T Cell Responses to Varicella Zoster Virus (VZV) Vaccine SLVP020
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01911065|
Recruitment Status : Completed
First Posted : July 30, 2013
Results First Posted : March 3, 2017
Last Update Posted : April 21, 2017
|Condition or disease||Intervention/treatment||Phase|
|Herpes Zoster||Biological: Zostavax™||Phase 4|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||54 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||T Cell Responses to Varicella Zoster Virus After Vaccination and Viral Escape|
|Study Start Date :||September 2010|
|Primary Completion Date :||December 2011|
|Study Completion Date :||December 2011|
Experimental: Zostavax™ vaccine group
Participants > 50 years will receive a single dose 0.65 ml Zostavax™ (live, attenuated zoster vaccine) administered by subcutaneous injection.
In the Vaccination arm, healthy individuals will be vaccinated with the licensed zoster vaccine, Zostavax.
Other Name: Zoster Vaccine Live
No Intervention: Natural-acquired VZV immunity
Participants 40-49 years of age will not receive any intervention with the objective of examining the influence of age and inherited factors on the varicella zoster virus (VZV)-specific immune response in those with a naturally-acquired VZV immunity (a prior history of chicken pox).
- Number of Participants Who Received Zostavax Immunization or Had Natural Exposure to VZV [ Time Frame: Day 0 to Day 35 ]
- Number of Participants With Related Adverse Events [ Time Frame: 0 to 35 Days ]
- Identify Predictors That Correlate With a Rapid and Diverse T Cell Response. [ Time Frame: 0 to 14 Days ]The investigators will use the frequency and TCR diversity of VZV-specific T cells on days 7 and 14 after vaccination as outcome variable and identify predictors that positively or negatively correlate with a rapid and diverse T cell response in the different age groups.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01911065
|United States, California|
|Stanford University School of Medicine|
|Stanford, California, United States, 94305|
|Principal Investigator:||Cornelia L Dekker, MD||Stanford University|
|Principal Investigator:||Jorg J Goronzy, MD, PhD||Stanford University|